Lisata Therapeutics, Inc.
LSTA
$2.26
$0.17568.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.43% | 8.13% | -21.30% | -8.32% | -9.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.26% | -10.53% | -19.67% | -3.55% | -7.87% |
| Operating Income | 17.86% | 10.53% | 19.67% | 3.55% | 7.87% |
| Income Before Tax | 14.07% | 6.29% | 20.65% | -0.19% | 10.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.07% | 6.29% | -25.25% | 12.70% | 10.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.07% | 6.29% | -25.25% | 12.70% | 10.43% |
| EBIT | 17.86% | 10.53% | 19.67% | 3.55% | 7.87% |
| EBITDA | 17.90% | 10.53% | 19.77% | 3.55% | 7.93% |
| EPS Basic | 16.66% | 8.31% | -20.91% | 15.93% | 13.53% |
| Normalized Basic EPS | 16.18% | 8.32% | 23.38% | 5.06% | 10.29% |
| EPS Diluted | 16.66% | 8.31% | -21.49% | 15.93% | 13.69% |
| Normalized Diluted EPS | 16.18% | 8.32% | 23.38% | 5.06% | 10.29% |
| Average Basic Shares Outstanding | 3.11% | 2.21% | 3.58% | 3.84% | 3.57% |
| Average Diluted Shares Outstanding | 3.11% | 2.21% | 3.58% | 3.84% | 3.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |